Abstract: Disclosed are compositions comprising antiseptic and wound healing agents for the treatment of diseases of the lower respiratory tract and methods.
Abstract: Highly efficient cationic liposomes have been developed as an improved delivery system for biologically-active reagents. A novel structure, the sandwich liposome, is formed and comprises one or more biologically active agents internalized between two bilomellar liposomes. This structure protects the incoming agent and accounts for the high efficiency of in vivo delivery and for the broad tissue distribution of the sandwich liposome complexes. These novel liposomes are also highly efficient carriers of nucleic acids. By using extruded DOTAP:cholesterol liposomes to form complexes with DNA encoding specific proteins, expression has been improved dramatically. Highest expression was achieved in the lung, while increased expression was detected in several organs and tissues.
Type:
Grant
Filed:
February 21, 2006
Date of Patent:
October 30, 2007
Assignee:
United States of America as represented by the Secretary, Department of Health and Human Services
Inventors:
Nancy Smyth-Templeton, George N. Pavlakis
Abstract: The invention is generally related to the field of formulating medicaments in association with a solid support. Such formulations comprising photosensitizers, and their use in photodynamic therapy, are also provided. Methods for the production of the medicament formulations are also disclosed.
Abstract: A composition for administration of a therapeutically effective dose of a topoisomerase inhibitor I or topoisomerase I/II inhibitor is described. The composition includes liposomes having an outer surface and an inner surface defining an aqueous liposome compartment, and being composed of a vesicle-forming lipid and of a vesicle-forming lipid derivatized with a hydrophilic polymer to form a coating of hydrophilic polymer chains on both the inner and outer surfaces of the liposomes. Entrapped in the liposomes is the topoisomerase inhibitor at a concentration of at least about 0.10 ?mole drug per ?mole lipid.
Type:
Grant
Filed:
October 8, 2004
Date of Patent:
October 9, 2007
Assignee:
ALZA Corporation
Inventors:
James L. Slater, Gail T. Colbern, Peter K. Working
Abstract: Particles having a tap density less than about 0.4 g/cm3 are formed by spray drying from a colloidal solution including a carboxylic acid or salt thereof, a phospholipid, a divalent salt and a solvent such as an aqueous-organic solvent. The colloidal solution can also include a therapeutic, prophylactic or diagnostic agent. Preferred carboxylic acids include at least two carboxyl groups. Preferred phospholipids include phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, phophstidylserines, phosphatidylinositols and combinations thereof. The particles are suitable for pulmonary delivery.
Type:
Grant
Filed:
April 28, 2004
Date of Patent:
October 9, 2007
Assignee:
Advanced Inhalation Research, Inc.
Inventors:
Michael W. Lipp, Richard P. Batycky, Giovanni Caponetti
Abstract: The present invention is directed to a method for delivering agents to the central nervous system by way of a tissue innervated by the trigeminal nerve that is outside the nasal cavity. Such a method of delivery can be useful in the treatment of central nervous system and/or brain disorders.
Type:
Grant
Filed:
November 21, 2002
Date of Patent:
September 25, 2007
Assignee:
Chiron Corporation
Inventors:
William H. Frey, II, Robert Gary Thorne
Abstract: Methods and compositions for triggering the delivery of an encapsulated therapeutic agent from a liposome are provided. Liposomes of opposite charge and incorporating lipids which favor non-lamellar structures are contacted in vivo. At least one of the liposome encapsulates at least one therapeutic drug or agent. Preferably, the liposomes have a fusogenic hydrophillic coating, such as PEG to control the rate of interaction of the liposomes and release of the therapeutic agent.
Type:
Grant
Filed:
May 19, 2003
Date of Patent:
September 25, 2007
Assignee:
University of British Columbia
Inventors:
Igor V. Zhigaltsev, Kim F. Wong, Norbert Maurer, Pieter R. Cullis
Abstract: Lipid emulsion compositions and methods of using such composition via intravenous infusion to reduce the bioavailability and toxicity of poisonous agents in the bloodstream.
Abstract: Fenofibrate microparticles are prepared using a combination of surface modifiers with a phospholipid. Particle size growth and stability are controlled while significantly smaller sized fenofibrate particles are produced.
Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.
Type:
Grant
Filed:
August 23, 2000
Date of Patent:
August 7, 2007
Assignee:
Advanced Inhalation Research, Inc.
Inventors:
Richard P. Batycky, Michael M. Lipp, Ralph W. Niven
Abstract: This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.
Type:
Grant
Filed:
February 18, 2004
Date of Patent:
July 24, 2007
Assignees:
Board of Regents, The University of Texas System, Inex Pharmaceuticals Corporation
Inventors:
Andreas H Sarris, Fernando Cabanillas, Patricia M Logan, Clive T R Burge, James H Goldie, Murray S Webb
Abstract: This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.
Type:
Grant
Filed:
December 4, 2003
Date of Patent:
July 17, 2007
Assignees:
Inex Pharmaceuticals Corporation, Board of Regents, The University of Texas System
Inventors:
Andreas H. Sarris, Fernando Cabanillas, Patricia M. Logan, Clive T. R. Burge, James H. Goldie, Murray S. Webb
Abstract: This invention relates to liposomal antineoplastic agents (e.g., camptothecin) compositions and methods of using such compositions for treating neoplasia and for inhibiting angiogenesis. The compositions and methods are useful for modulating the plasma circulation half-life of an active agent.
Type:
Grant
Filed:
June 29, 2001
Date of Patent:
July 17, 2007
Assignee:
Tekmira Pharmaceuticals Corporation
Inventors:
Thomas D. Madden, Sean C. Semple, Quet F. Ahkong
Abstract: A composition for administration of a therapeutically effective dose of a topoisomerase inhibitor I or topoisomerase I/II inhibitor is described. The composition includes liposomes having an outer surface and an inner surface defining an aqueous liposome compartment, and being composed of a vesicle-forming lipid and of a vesicle-forming lipid derivatized with a hydrophilic polymer to form a coating of hydrophilic polymer chains on both the inner and outer surfaces of the liposomes. Entrapped in the liposomes is the topoisomerase inhibitor at a concentration of at least about 0.10 ?mole drug per ?mole lipid.
Type:
Grant
Filed:
August 29, 2002
Date of Patent:
July 17, 2007
Assignee:
Alza Corporation
Inventors:
James L. Slater, Gail T. Colbern, Peter K. Working
Abstract: This invention provides an aqueous/t-butanol solvent-system, facile reconstitute, submicron-reconsitiute preliposome-lyophilaye and method of its preparation and use. In one embodiment this entails a modified method for the preparation of a submicron and stable liposome formulation of the non-cross-resistant anthracycline Annamycin is described. The optimal lipid composition was DMPC:DMPG at a 7:3 molar ratio and the optimal lipid:drug weight ratio 50:1. The selected formulation is a preliposome lyophilized powder that contains the phospholipids, Annamycin, and 1.7 mg Tween 20 per mg of Annamycin. The liposome suspension is obtained on the day of use by adding normal saline at 37° C. (1 ml per mg Annamycin) and hand-shaking for one minute. The presence of Tween 20 is essential in shortening the reconstitution step (from >2 hours to 1 minute), avoiding the early formation of free drug crystals, and reducing the median particle size (from 1.5 ?m to 0.15-0.20 ?m) without destruction of the liposome vesicles.
Type:
Grant
Filed:
July 24, 1998
Date of Patent:
July 3, 2007
Assignee:
Board of Regents, The University of Texas System
Inventors:
Yiyu Zou, Waldemar Priebe, Roman Perez-Soler
Abstract: Pharmaceutical compositions comprising a cyclosporin, e.g. Ciclosporin or [Nva]2-Ciclosporin, in “microemulsion pre-concentrate” and microemulsion form. The compositions typically comprise (1.1) a C1-5alkyl or tetrahydrofurfuryl di- or partial-ether of a low molecular weight mono- or poly-oxy-alkane diol, e.g. Transcutol or Glycofurol, as hydrophilic component. Compositions are also provided comprising a cyclosporin and (1.1) and, suitably, also a saccharide monoester, e.g. raffinose or saccharose monolaurate. Dosage forms include topical formulations and, in particular, oral dosage forms.
Type:
Grant
Filed:
October 2, 2002
Date of Patent:
June 26, 2007
Assignee:
Novartis AG
Inventors:
Birgit Hauer, Armin Meinzer, Ulrich Posanski, Friedrich Richter
Abstract: The present invention provides biocompatible vesicles comprising semi-permeable, thin-walled encapsulating membranes which are formed in an aqueous solution, and which comprise one or more synthetic super-amphiphilic molecules. When at least one super-amphiphile molecule is a block copolymer, the resulting synthetic vesicle is termed a “polymersome.” The synthetic, reactive nature of the amphiphilic composition enables extensive, covalent cross-linking of the membrane, while maintaining semi-permeability. Cross-linking of the polymer building-block components provides mechanical control and long-term stability to the vesicle, thereby also providing a means of controlling the encapsulation or release of materials from the vesicle by modifying the composition of the membrane. Thus, the encapsulating membranes of the present invention are particularly suited for the reliable, durable and controlled transport, delivery and storage of materials.
Type:
Grant
Filed:
July 1, 2004
Date of Patent:
May 15, 2007
Assignees:
The Trustees of the University of Pennsylvania, Regents of the University of Minnesota
Inventors:
Dennis E. Discher, Bohdana M. Discher, You-Yeon Won, James C-M Lee, Daniel A. Hammer, Frank Bates
Abstract: In accordance with the present invention, there are provided lipid-conjugated polyamide compounds and related compositions and methods thereof. Lipid-conjugated polyamide compounds of the present invention are particularly useful as vehicles for delivering biologically active agents to a target site. In particular, the invention compounds are effective at facilitating the delivery of polynucleotides to cells. The present invention also provides a method for producing stable formulations of polynucleotides complexed with a delivery vehicle.
Type:
Grant
Filed:
May 27, 2003
Date of Patent:
May 8, 2007
Assignee:
Novartis Vaccines And Diagnostics, Inc.
Inventors:
Ronald N. Zuckermann, Chin-Yi Huang, John E. Murphy, Tetsuo Uno
Abstract: This invention comprises a method of treating a subject having relapsed or refractory cancer such as leukemia with liposomal annamycin including the steps of (a) evaluating the subject to determine if the subject has relapsed or refractory cancer; (b) administering a high-dose amount of liposomal-annamycin for at least 3 days in a 7 day period. First line cancer therapy with particular reference to leukemia is both contemplated and useful.
Type:
Grant
Filed:
June 10, 2005
Date of Patent:
April 17, 2007
Assignee:
Board of Regents, The University of Texas System